Breast Clinical Trials
Study Name: ALISCA-Breast1
- Cancer Stage: IV
- Key Inclusion: HR+/HER 2-
- Description: A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Study Number: PUMA-ALI- 1201
- NCT#: NCT06369285
Study Name: EvoPAR-BR01
- Cancer Stage: IV
- Key Inclusion: BRCA1, BRCA2, PALB2
- Description: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Study Number: D9722C00001
- NCT#: NCT06380751
Study Name: Elaine III
- Cancer Stage: IV
- Key Inclusion: ESR1m, ER+/HER2
- Description: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)
- Study Number: SMX22-002
- NCT#: NCT05696626
Study Name: (CAPItello-292)
- Cancer Stage: IV
- Key Inclusion: HR+/HER2-
- Description: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- Study Number: D361DC00001
- NCT#: NCT04862663
Study Name: ASCENT-05
- Cancer Stage: I-III
- Key Inclusion: TNBC; Residual Disease
- Description: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63).
- Study Number: GS-US-595-6184
- NCT#: NCT05633654
Study Name: OFSET
- Cancer Stage: I-II
- Key Inclusion: Oncotype 16-26
- Description: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
- Study Number: NRG-BR009
- NCT#: NCT05879926
Study Name: pionERA
- Cancer Stage: IV
- Key Inclusion: ER+; HER2-
- Description: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer).
- Study Number: C044657
- NCT#: NCT04576455
Study Name: CC011
- Cancer Stage: I-III
- Key Inclusion: Survivor
- Description: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors.
- Study Number: NRG-CC011
- NCT#: NCT05896189
Study Name: OptimICE-PCR
- Cancer Stage: I-II
- Key Inclusion: CR TNBC Adjuvant
- Description: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab.
- Study Number: A012103
- NCT#: NCT05812807
Study Name: Scarlet
- Cancer Stage: N/A
- Key Inclusion: N/A
- Description: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
- Study Number: S2212
- NCT#: NCT05929768
-
Frederick, MD 21702
301-694-5861 More Information -
Frederick, MD 21702
301-663-4774 More Information -
Frederick, MD 21702
240-215-6310 More Information -
Frederick, MD 21702
301-694-5580 More Information -
Frederick, MD 21702
240-566-4100 More Information -
Frederick, MD 21702
240-566-4100 More Information -
Frederick, MD 21702
240-566-4500 More Information
/
View All